TCT In Brief
This article was originally published in The Gray Sheet
Executive Summary
HORIZONS-AMI: Two-year follow-up results from the 3,000-patient randomized trial show that ischemia-driven target lesion revascularization - the primary endpoint of the study - was 6.8% in patients receiving Boston Scientific's Taxus Express stent compared to 11.6% for those treated with a bare metal stent, firm reports during the Transcatheter Cardiovascular Therapeutics conference in San Francisco. For the secondary endpoint, target vessel revascularization, the rates for the Taxus Express and bare metal stent groups were 8.9% and 13.3%, respectively. The rate of major adverse cardiac events at two years was 11% for the drug-eluting stent and 11.2% for the bare metal stent. HORIZONS-AMI is designed to assess the safety and efficacy of Taxus Express in high-risk acute myocardial infarction patients